Last reviewed · How we verify

NCT05437887

Effects of Fucoidan on the Gut Microbiota in the Patients of Atopic Dermatitis

Status unknown NA Last updated 6 December 2022
What this trial tests

NA trial testing Fucoidan in Atopic Dermatitis in 40 participants. Status unknown.

Timeline
4 October 2022
Primary endpoint
6 March 2024
6 March 2024

Quick facts

Lead sponsorChang Gung Memorial Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date4 October 2022
Primary completion6 March 2024
Estimated completion6 March 2024
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 6 to 60, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Forty patients with physician-identified atopic dermatitis will be enrolled in the study. All patients must be aged between 6 and 60 years old. All patients consumed fucoidan for 3 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Immunopotentiating Activity of Fucoidans and Relevance to Cancer Immunotherapy.
    Li Y, McGowan E, Chen S, Santos J, et al · · 2023 · cited 22× · PMID 36827169 · DOI 10.3390/md21020128

Verify or expand the search:

Other trials of Fucoidan

Trials testing the same drug.

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

Other Chang Gung Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05437887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing